A specialty pharmaceutical company focused on the development and commercialization of difficult to make products.
ABOUT US
Partnerships​
Our aim is to be a partner that you can trust and foster relationships where the whole is greater than the sum of its parts.
Products
We focus on developing difficult generic and 505(b)(2) products. Through our strong domestic and global partnerships, products will include both patented and off-patented brands and generics.
Markets
We target products to the retail, institutional and specialty pharmaceutical markets. Prioritizing patient access is one of our key Company Values.
PIPELINE
OMN-OS-200
Epilepsy
Oral Solid
Launch: Q2 2022
OMN-IN-300
Hypertension
Injection
Launch: Q3 2023
OMN-IN-400
Acidosis
Injection
Launch: Q4 2022
OMN-IN-500
Epilepsy
Oral Solid
Launch: Q2 2022
OMN-7200
Hypertension
Injection
Launch: Q3 2023
OMN-7300
Acidosis
Injection
Launch: Q4 2022
DROP US A LINE!
We look forward to connecting
We’re happy to share more about the scope of our products, team, markets and answer questions. Reach out and we’ll schedule a time to connect.
© 2025 Copyright . All rights reserved.
Omnivium Pharmaceuticals LLC
2131 Felver Court, Suite A, Rahway, New Jersey 07065, United States